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ABSTRACT: Impairment of the ubiquitin-proteasome degradation system has recently been suggested to be
related to the onset of neurodegenerative disorders such as Alzheimer0s disease and Parkinson’s disease.
In this study, we investigated whether intracellular R-synuclein affects proteasome activity in SH-SY5Y cells.
To monitor intracellular proteasome activity, we used a reporter consisting of a short peptide degron fused to
the carboxyl-terminus of green fluorescent protein (GFP-CL1), which is known to be degraded by
proteasome. The level of intact GFP-CL1 was dramatically increased by coexpression of GFP-CL1 and
R-synuclein, as judged by confocal microscopic and immunoblot analyses. Expression of two pathogenic
mutants of R-synuclein, A30P and A53T, and phosphomimetic S129D mutant increased the intensities of
GFP more effectively than did wild-type R-synuclein. GFP fluorescence in cells transfected with Δ73-83
mutantorβ-synuclein,whichdoesnotassembleintofilamentsinvitro,wasnotchangedascomparedwiththat
in cells expressing GFP-CL1 alone. Thus, the ability of R-synuclein to inhibit proteasome activity is related to
its propensity to assemble into filaments. Furthermore, we observed that some compounds inhibiting
R-synuclein filament formation in vitro prevented the R-synuclein-mediated proteasome dysfunction in cells
transfected with both GFP-CL1 and R-synuclein. The cellular model expressing both GFP-CL1 and
R-synuclein may be a useful tool to screen compounds protecting neurons from R-synuclein-mediated
proteasome dysfunction.
Parkinson’s disease (PD) is one of the most common neuro-
degenerative disorders. It is characterized by loss of dopaminer-
gic neurons in the substantia nigra and by intracellular inclusion
bodiesknownasLewybodiesandLewyneuritis.R-Synucleinisa
natively unfolded protein and is deposited in a hyperphosphory-
lated form as the major component of these filamentous inclu-
sions (1-3). Genetic studies have revealed that missense
mutations (A30P, E46K, and A53T) in the R-synuclein gene
cause familial forms of PD and dementia with Lewy bodies
(DLB) (4-6). It has also been reported that multiplications
(duplication and triplication) of R-synuclein gene cause an
inherited form of PD and DLB (7-11). Thus, an increased level
of intracellular R-synuclein is thought to contribute to the onset
of familial PD.
Intracellular and extracellular protein deposits may cause
neuronal cell death and may signal onset of many neurodegen-
erative diseases. We have reported that phosphorylated
R-synuclein is partially ubiquitinated in R-synucleinopathy
brains (12). We also found that ubiquitination of R-synuclein
occurs in cultured cells at sites identical to those of filamentous
R-synuclein ubiquitinated in vitro, suggesting that ubiquitination
maybealateeventintheformationofLewybodies(13).Arecent
paper confirmed our findings and showed that monoubiquitina-
tion and multiubiquitination at Lys12, 21, and 23 are detectable
on phosphorylated R-synucleininR-synucleinopathybrains(14).
These findings indicate that the ubiquitin-proteasome system
(UPS) is targeted to abnormal R-synuclein in the brains of
patients but that ubiquitinated R-synuclein cannot be degraded
bytheUPS,suggestingthattheUPSmaynotbeeffectivetoclear
the abnormal form of R-synuclein.
The UPS functions in cellular quality control by degrading
misfolded, unassembled, or damaged proteins that might create
toxic intracellular aggregates (15, 16). As the proteasome effi-
ciently degrades multiubiquitinated proteins, the presence of
elevated levels of ubiquitin conjugates in intracellular deposits
of aggregated proteins in most neurodegenerative diseases
suggests a linkage between UPS dysfunction and pathogenesis.
Functional relationships between R-synuclein and the UPS
have been described (17-19). Synder et al. reported that aggre-
gated and monomeric R-synuclein inhibit proteasomal function
in vitro (20). Lindersson et al. also observed proteasomal inhibi-
tion by R-synuclein filaments and oligomers in vitro (21). In
cultured cells, it remains controversial whether expression of
R-synuclein affects intracellular proteasome activity. Martin-
Clemente et al. reported that R-synuclein expression level does
not significantly affect proteasome function in PC12 cells (22),
while Fujita et al. reported that proteasome activity was sig-
nificantly decreased in cells overexpressing wild-type R-synu-
clein (23). Stefanis et al. described that expression of A53T
mutant, but not wild-type R-synuclein, inhibits proteasome
activity inPC12 cells(24).Itwasalsoreported thatcell-produced
R-synuclein oligomers are targeted to and impair the 26S
proteasome (25).
Recently, Bence et al. reported impairment of the ubiquitin-
proteasome system by the expression of an exon 1 fragment of
†This work was supported by a Grant-in-Aid for Scientific Research
on Priority Areas-Research on Pathomechanisms of Brain Disorders
(to M.H., 20023038) and Grants-in-Aid for Scientific Research (B) (to
M.H., 18300117) and (C) (to T.N., 19590297) from the Ministry of
Education, Culture, Sports, Science and Technology of Japan.
*To whom correspondence should be addressed. Phone: þ81-3-3304-
5701. Fax: þ81-3-3329-8035. E-mail: nonakat@prit.go.jp, masato@
prit.go.jp.Article Biochemistry, Vol. 48, No. 33, 2009 8015
huntingtin containing expanded polyglutamine homopolymer in
cultured cells (26). They used a green fluorescent protein (GFP)
reporter that is specifically degraded by the cellular proteasome.
This fluorescent reporter system is also useful for facile detection
of proteasome activity in Caenorhabditis elegans (27).
In this study, to investigate whether intracellular R-synuclein
affects proteasome activity, we have established a more sensitive
assay system to monitor proteasome activity in cells using the
GFP reporter and demonstrated impairment of proteasome
function byexpression of R-synuclein in SH-SY5Y cells. We also
found that two pathogenic mutations of R-synuclein (A30P and
A53T) and S129D mutant, which mimics phosphorylation,
inhibit proteasome activity more effectively than does wild-type
R-synuclein, while Δ73-83 mutant and β-synuclein, which do not
form fibrils in vitro, do not affect proteasome function. Further-
more, we used our cellular model to screen for compounds
protecting cells from proteasome inhibition by R-synuclein and
found that some polyphenols attenuate R-synuclein-induced
proteasome impairment.
EXPERIMENTAL PROCEDURES
Construction of Plasmids. The GFP-CL1 plasmid was
constructed by digestion of pEGFP-C1 (Clontech) with BglII
and SalI and ligation with hybridized oligonucleotides termed
CL1s (50-GATCCGCTTGTAAAAATTGGTTTTCTTCTTT-
ATCTCATTTTGTTATTCATTTATAAG-30) and CL1a (50-
TCGACTTATAAATGAATAACAAAATGAGATAAAGA-
AGAAAACCAATTTTTACAAGCG-30). The resulting con-
struct, the GFP gene containing an oligonucleotide encoding
ACKNWFSSLSHFVIHL, was confirmed byDNA sequencing
and designated pEGFP-CL1.
Human R-synuclein, β-synuclein, tau 3R1N, and 4R1N
cDNAs in pRK172 vector were kind gifts from Dr. M. Goedert.
The open reading frames of R-synuclein, β-synuclein, tau 3R1N,
and4R1Nweresubclonedintothemammalianexpressionvector
pcDNA3. To construct plasmids encoding R-synuclein mutants
A30P, A53T, S129A, and S129D, we performed site-directed
mutagenesis using a site-directed mutagenesis kit (Strategene).
We constructed a deletion mutant (residues 73-83: Δ73-83) of
R-synuclein using PCR with the forward primer (50-GGAG-
CAGGGAGCATTGCAGCA-30) and the reverse primer (50-
CGTCACCACTGCTCCTCCAAC-30) using pcDNA3-R-synu-
clein as a template. The amplified fragments were self-ligated,
and the resulting plasmids designated pcDNA-R-synuclein
Δ73-83. All constructs were verified by DNA sequencing.
CellCultureandPlasmidExpression. SH-SY5Ycells were
cultured in DMEM/F12 medium (Sigma) supplemented with
10% (v/v) fetal calf serum, Penicillin-Streptomycin-Glutamine
(GIBCO), and MEM Non-Essential Amino Acids Solution
(GIBCO). The cells were maintained at 37 Ci nah u m i d i f i e d
atmosphere of 5% (v/v) CO2. Cells were grown to 50% con-
fluenceinsix-wellculturedishesfortransientexpressionandthen
transfected with various expression plasmids using FuGENE6
(Roche) according to the manufacturer0s instructions.
Confocal Immunofluorescence Microscopy. SH-SY5Y
cellsweregrownonacoverslip(15mm 15mm)andtransfected
with expression vector (total 1.3 μg, e.g., 1 μgo fp c D N A 3 -
R-synuclein plus 0.3 μg of pEGFP-CL1). After incubation for
indicatedtimes,transfectedcellsonthecoverslipswerefixedwith
4% (w/v) paraformaldehyde in phosphate-buffered saline (PBS)
for 30 min. The coverslips were then incubated in 50 mM NH4Cl
in PBS for 10 min, and cell permeabilization was performed
with 0.2% (v/v) Triton X-100 in PBS for 10 min. The cells
wereblockedfor30minin5%(w/v) BSAinPBS,thenincubated
with anti-R-synuclein monoclonal antibody, Syn102 (28)
(1:500 dilution) for 1 h at 37 C, followed by TRITC-labeled
goat anti-mouse IgG (Sigma, 1:500 dilution) as the secondary
antibody for 1 h at 37 C. They were washed again and further
incubated with TO-PRO-3 (Molecular Probes, 1:3000 dilution
in PBS) for 45 min at 37 C to stain nuclear DNA and analyzed
using a LSM5 Pascal confocal laser microscope (Zeiss).
Sequential Extraction of Proteins and Immunoblotting.
SH-SY5Y cells were grown in a six-well plate and transiently
transfected with expression plasmids (total 1.3 μg). After incuba-
tion for 48-72 h, cells were harvested and lysed in TS buffer
[50 mM Tris-HCl buffer, pH 7.5, 0.15 M NaCl, 5 mM ethylene-
diaminetetraacetic acid, 5 mM ethylene glycol bis(β-aminoethyl
ether)-N,N,N,N-tetraacetic acid, and protease inhibitor cocktail
(Roche)]. The lysate was centrifuged at 290,000g for 20 min at
4 C, and the supernatant recovered as the TS-soluble frac-
tion. The TS-insoluble pellet was lysed in TS buffer containing
1% (v/v) Triton X-100 (TX) and centrifuged at 290,000g for
20 min at 4 C. The supernatant was collected as the TX-soluble
fraction. The TX-insoluble pellet was further lyzed in SDS-
sample buffer and heated for 5 min. Protein concentration was
estimated by using the BCA Protein Assay Kit (Pierce). Samples
(20 μg) were separated by 13.5% (v/v) SDS-PAGE using the
Tris-tricine buffer system and proteins were transferred onto
polyvinylidene difluoride membrane (Millipore). The blots were
then blocked with 3% (v/v) gelatin and incubated overnight with
anti-GFP monoclonal antibody (MBL), anti-Syn102, anti-hu-
man tau monoclonal antibody (HT7, Thermo Scientific) or anti-
R-tublinmonoclonalantibody(Sigma)in10%(v/v)calfserumat
a dilution of 1:1,000-5,000 at room temperature. After washing,
blots were incubated with horseradish peroxidase-labeled sec-
ondaryantibody(Bio-Rad) at a dilution of1:10,000 in10% (v/v)
calf serum for 1 h at room temperature or a biotin-labeled
secondaryantibody(Vector)for2hatroomtemperature.Signals
were detected using the chemiluminescence reagent Immunostar
(Wako) or the ABC staining kit (Vector).
Measurement of Proteasome Activity Using a Peptide
Substrate. SH-SY5Y cells transfected with expression plasmids
wereculturedfor72hortreatedwith20μMMG132for6h.Cells
were harvested and cytosolic fraction was prepared as follows.
Cells were resuspended in 100 μL of phosphate-buffered saline
(PBS) and disrupted by sonication. Insoluble material was
removed by ultracentrifugation at 290,000g for 20 min at 4 C.
The supernatant was assayed for proteasome activity by using a
fluorescent peptide substrate, benzyloxycarbonyl-Leu-Leu-Glu-
7-amido-4-methylcoumarin (z-LLE-MCA, Peptide Institute,
Inc.). Aliquots (10 μL) were mixed with 0.1 M Tris-HCl buffer,
pH 7.5 and water in a total volume of 1 mL. After preincubation
at37 Cfor10min,10μL of 10mMpeptidesubstratewas added
andthemixturewasincubatedfor30min.Asolutionof2%(v/v)
acetic acid (1 mL) was added to the reaction mixture, and
7-amino-4-methylcoumarin (AMC) release was measured fluor-
ometrically (excitation wavelength of 365 nm; emission wave-
length of 460 nm). Enzyme activity was described as arbitrary
unit/mg protein.
Screening for Compounds Preventing Proteasome Inhi-
bition by R-Synuclein in Cultured Cells. SH-SY5Y cells
were grown in six-well plates or on coverslips and transfected
with both R-synuclein (1 μg) and GFP-CL1 plasmids (0.3 μg).8016 Biochemistry, Vol. 48, No. 33, 2009 Nonaka and Hasegawa
Various compounds (all at 40 μM) were added to the culture
medium 2 h after transfection. Cells were harvested after
incubation for 72 h, and the immunoblot and/or confocal
microscopic analyses were performed as above. A decrease in
GFP level in transfected cells treated with a compound, com-
pared with the GFP level in transfected cells without such
treatment, indicated that the compound rescues cells from
proteasome dysfunction caused by expression of R-synuclein.
RESULTS
Cellular Expression of GFP-CL1. To establish a sensitive
and convenient assay system for proteasome activity in cultured
cells, we constructed GFP-CL1, which is GFP fused at the
C-terminus with the 16-residue degron peptide CL1 (26, 29).
We transiently transfected SH-SY5Y cells with GFP or GFP-
CL1,andanalyzedthecellsusingconfocalmicroscopy.Asshown
in Figure 1A, the fluorescence of GFP in cells transfected with
GFP-CL1 was less than that in cells expressing GFP. The
proteasome inhibitor MG132 increased fluorescence intensity
inGFP-CL1-transfectedcells(Figure 1A).Thus, wereconfirmed
that the CL1 sequence specifically targeted normally stable
GFP for efficient degradation by proteasome, as reported pre-
viously (26).
To biochemically characterize the proteasomal degradation of
GFP-CL1, we fractionated lysates of cells transfected with GFP-
CL1 or GFP. The TS-, TX-, and SDS-soluble fractions were
analyzed by immunoblotting using anti-GFP antibody. As
shown in Figure 1B, almost all GFP was recovered in the TS
fraction in cells transfected with GFP, although a little GFP was
detected in the TX-soluble fraction. In contrast, in cells expres-
sing GFP-CL1, only weak GFP immunoreactivity was detected
in the TS- and TX-insoluble fractions because of GFP-CL1
degradation by proteasome in transfected cells. Interestingly, in
cells expressing GFP-CL1 treated with MG132, a band of
uncleaved GFP-CL1 was detected in the SDS-soluble fraction
in addition to the weak bands seen in the TS- and TX-soluble
fractions, suggesting that uncleaved GFP-CL1 unexpectedly
aggregates in cells when proteasome activity is inhibited by
MG132 treatment. We also reconfirmed that MG132 treatment
effectively and dose-dependently blocked the degradation of
GFP-CL1 (Figure 1C).
Expression of R-Synuclein Inhibits Cellular Proteasome
Activity.ToinvestigatewhetherexpressionofR-synucleinmight
affect proteasome function in cultured cells, we cotransfected
both R-synuclein and GFP-CL1 into SH-SY5Y cells. To recon-
firm that GFP-CL1 is effectively degraded by proteasome, cells
transfected with GFP-CL1 were treated with several protease
inhibitors. SDS-soluble fraction of cell lysate was subjected to
immunoblot analysis using anti-GFP antibody. As shown in
Figure 2A, increased levels of GFP-CL1 band were observed in
cells coexpressing GFP-CL1 and R-synuclein (lane 6), indicating
that proteasome activity is inhibited effectively by expression of
R-synuclein. Similar results were obtained when we treated cells
expressing GFP-CL1 with MG132 or lactacystin (lane 3 and 4).
On the other hand, leucyl-leucinal (LL, a calpain inhibitor) or
chloroquine (a lysosomal inhibitor) did not inhibit GFP-CL1
degradation (lanes 2 and 5). We then tested whether the pro-
teasome inhibition by R-synuclein is dose-dependent, i.e., depen-
dent on the R-synuclein expression level. SH-SY5Y cells were
FIGURE 1: GFP-CL1isdegradedbyproteasomeinSH-SY5Y cells.(A) SH-SY5Ycells grown oncoverslipsweretransfected withGFP orGFP-
CL1 using FuGENE6. After an overnight incubation with or without 1 μM MG132, cells were fixed (total 48 h after transfestion), stained with
TO-PRO-3 (Blue), and analyzed by confocal microscopy. Scale bar = 100 μm. (B) SH-SY5Y cells were transfected with GFP or GFP-CL1 and
treated overnight with or without 1 μM MG132. Cells were harvested, and cell lysate was fractionated as described in Experimental Procedures
and analyzed by immunoblotting using anti-GFP antibody. TS, Tris-soluble fraction; TX, Triton X-100-soluble fraction; SDS, SDS-soluble
fraction. (C) SH-SY5Y cells were transfected with GFP-CL1 and treated with MG132 (0-50 μM) for 6 h. The cells were harvested, and the
TX-insoluble fraction was analyzed by immunoblotting with anti-GFP antibody.Article Biochemistry, Vol. 48, No. 33, 2009 8017
transfected with both pEGFP-CL1 (0.3 μg) and pcDNA3-
R-synuclein (0, 0.2, 0.5, or 1 μg; total 1.3 μg plasmids), followed
byimmunoblotanalysis.Theresultshowedthatthelevelofintact
GFP-CL1 increased in parallel with increased expression of
R-synuclein (Figure 2B). Furthermore, wetested whether expres-
sion of tau protein which is also an effective substrate for
proteasome (30), inhibits intracellular proteasome activity in
SH-SY5Y cells. We found that expression of tau protein
(3R1N and 4R1N) did not affect the proteasome activity in
SH-SY5Y cells, suggesting that the effect of R-synuclein on the
proteasome activity observed in this study is not simply due
to overexpression of a protein, but is specific for R-synuclein.
We also confirmed the absence of significant cell death in our
cellular modeltransiently expressing R-synuclein, suggestingthat
the decreased proteasome activity found in cells expressing
R-synuclein is not caused by cellular damage due to the toxicity
of expressed R-synuclein.
To visually monitor proteasome inhibition due to expression
of R-synuclein, SH-SY5Y cells were transiently cotransfected with
R-synuclein and GFP-CL1, and transfected cells were analyzed by
confocalmicroscopy.AsshowninFigure3C,thenumbersofGFP-
positive cells were significantly increased in cells transfected with
wild-type R-synuclein and GFP-CL1, compared with cells trans-
fected with GFP-CL1 alone (Figure 3B). This is in good agreement
with the above immunoblotting data (Figure 2), indicating that
expression of R-synuclein inhibited proteasome activity.
FIGURE 2: ExpressionofR-synucleininhibitsproteasome activityinSH-SY5Y cells.(A) SH-SY5Y cells transfected withGFP-CL1 weretreated
with 1 μM LL, MG132, lactacystin, and chloroquine overnight. In the case of coexpression, cells were transfected with both GFP-CL1 and
R-synucleinusingFuGENE6.Thecellswereharvested,andtheTritonX-100-insolubleandSDS-solublefractionswerepreparedandanalyzedby
immunoblottingusing ananti-GFPantibody. The results ofquantitative analysisofthe GFP-CL1bands,expressed asmeans þ SD(n = 3),are
shownbelowtheblot.(B)SH-SY5YcellsweretransfectedwithGFP-CL1(0.3μg),R-synuclein(0,0.2,0.5,or1μg),and/orpcDNA3emptyvector
(totalplasmids=1.3μg)andincubatedfor72h.Thecellswereharvested,andthenTris-soluble(lowerpanels) andSDS-solublefractions(upper
panels)wereprepared.Immunoblotanalyseswereperformedusinganti-GFP(upperpanels)oranti-Syn102(lowerpanels)antibodies.Theresults
ofquantitativeanalysisoftheGFP-CL1bands,expressedasmeansþ SD(n=3),areshownbelowtheblot.(C)SH-SY5Ycellsweretransfected
withbothGFP-CL1(0.3μg)andR-synuclein(1μg)orpcDNA3-tau3R1Nor4R1Nvector(1μg)andincubatedfor72h.Thecellswereharvested,
andtheTX-insolublefractionwasanalyzedbyimmunoblottingwithanti-GFPantibody.TheTS-solublefractionwasalsoanalyzedbyusinganti-
Syn102, anti-HT7, and anti-tubulin antibodies (as a loading control).8018 Biochemistry, Vol. 48, No. 33, 2009 Nonaka and Hasegawa
Taken together, these results showed that proteasome activity
can be specifically and sensitively analyzed by monitoring the
fluorescence intensity or immunoreactivity of GFP-CL1 in
cultured cells and that the expression of R-synuclein impairs
cellular proteasome function.
Effects of Expression of R-Synuclein Mutants and
β-Synuclein on Proteasome Activity. Recombinant R-synu-
cleinwithapathogenicmutation(A30P,A53T,orE46K)ismore
prone to assemble into filaments in vitro than the wild-type
protein (31, 32)). β-Synuclein and γ-synuclein (33) and the
R-synuclein deletion mutant Δ73-83 (deletion of 73-83 residues)
did not form fibrils in vitro (Nonaka et al., unpublished data).
To study the effects of R-synuclein mutations on cellular pro-
teasome activity, we transiently cotransfected these mutants
and GFP-CL1 into SH-SY5Y cells and examined the cells
using confocal microscopy. As shown in Figure 3, we found
that increased GFP signals were observed in cells transfected
with A30P (Figure 3D) or A53T (Figure 3E) compared with the
signal seen in cells transfected with wild-type R-synuclein
(Figure 3C), although the expression levels of the R-synuclein
proteins were almost equal (Figure 3 and 4A). In contrast, little
GFP fluorescence was detected in cells transfected with the
R-synuclein deletion mutant Δ73-83 (Figure 3F) or β-synuclein
(Figure 3G).
We also quantitatively examined the effects of these R-synu-
clein mutations on proteasome activity using immunoblot ana-
lysis. SH-SY5Y cells were transfected with both GFP-CL1 and
wild-type R-synuclein, or the A30P, A53T, or Δ73-83 mutant, or
β-synuclein. Uncleaved GFP-CL1 was recovered in the TX-
insoluble (SDS-soluble) fraction as described above. As shown
inFigure 4A,the levelofuncleaved GFP-CL1 incellstransfected
with A53T was about 30% higher than that in cells transfected
with wild-type R-synuclein (Figure 4A, lane 4). A slightly higher
levelofGFP-CL1was detected incellstransfected with the A30P
mutant (Figure 4A, lane 3) compared with that in cells trans-
fectedwithwild-typeR-synuclein(Figure4A,lane2).Incontrast,
the level of GFP-CL1 in cells transfected with Δ73-83 or
β-synuclein was negligible, as was that in control cells
(Figure 4A, lane 5 and 6). The expression levels of R-synuclein
protein in Tris-soluble fractions were almost the same. These
results showed that mutants of R-synuclein that are prone to
aggregate in vitro have stronger inhibitory effects on cellular
proteasome activity than does the wild-type protein and that
Δ73-83 and β-synuclein, neither of which form fibrils in vitro,d o
not inhibit the proteasome.
Expression of Phosphomimetic R-Synuclein Mutant
S129D Enhanced Its Inhibition of Proteasome Activity.
Aggregated R-synuclein in brains of R-synucleinopathy patients
FIGURE 3: ExpressionofR-synucleinmutantsaffectsproteasomeactivityinSH-SY5Ycells.SH-SY5Ycellsgrownoncoverslipsweretransfected
withGFP (A), GFP-CL1 (B), or bothGFP-CL1 and wild-type R-synuclein (C), A30P (D), A53T (E),Δ73-83 (F), or β-synuclein (G). Cells were
fixed 72 h after transfection and stained with anti-Syn102 (Red) and TO-PRO-3 (blue). Intracellular R-synuclein inhibits proteasome activity in
cells expressing both GFP-CL1 and R-synuclein (arrows). Scale bar = 100 μm.Article Biochemistry, Vol. 48, No. 33, 2009 8019
is hyperphosphorylated at Ser129, and this post-translational
modification facilitates self-aggregation in vitro (3). Altering
Ser129 to the negatively charged residue Asp (S129D) to mimic
phosphorylation significantly enhances R-synuclein toxicity in a
Drosophila model (34). We asked whether phosphorylation of
R-synuclein might affect proteasome activity in cultured cells.
SH-SY5Y cellswere transfected withGFP-CL1 andwild-typeor
mutant R-synuclein. Immunoreactivity of GFP-CL1 in cells
transfected with S129A was similar to that of cells transfected
with wild-type R-synuclein, while the levels of GFP-CL1 in cells
expressing S129D mutant to mimic phosphorylation was sig-
nificantlyhigherthanthose incells transfectedwiththe wild-type
or S129A (Figure 4B). These results suggested that phosphoryla-
tionofSer129mayfacilitateinhibitionofproteasomefunctionby
intracellular R-synuclein.
Comparison of Proteasome Activity Assay Using GFP-
CL1 with a Conventional Cleaving Assay Using a Fluor-
escent Peptide Substrate. To compare the sensitivity of the
assay of proteasome activity using GFP-CL1 with that of the
conventional assay using a fluorescent peptide, we evaluated
biochemically the proteasome activity of lysates from cells
transfected with R-synuclein. SH-SY5Y cells were transfected
with wild-type R-synuclein for 72 h, and proteasome activity in
cell lysates was measured using a peptide substrate specific for
proteasome, zLLE-MCA. As shown in Figure 5, zLLE-MCA-
cleaving activity in cells transfected with wild-type R-synuclein
was decreased slightly (∼10% inhibition) compared with that in
cells transfected with empty vector, while MG132 had a potent
inhibitory effect on proteasome activity (∼80% inhibition). On
theotherhand,asdescribedabove,thelevelsofGFP-CL1incells
transfectedwithGFP-CL1andR-synucleinwereincreasedabout
5 times compared with those in cells expressing GFP-CL1
(Figure 4A).
AsshowninFigure5,thezLLE-MCA-cleavingactivityincells
transfectedwithA30Pwasalmostequaltothatincellsexpressing
A53T,whichinturnwasdecreasedslightlycomparedwiththatin
cells transfected with wild-type R-synuclein. Proteasome activity
in cells transfected with Δ73-83 was found to be the same as
that in cells transfected with empty vector. It was also revealed
that S129D had a slightly stronger inhibitory effect on protea-
some activity than did wild-type R-synuclein. Taken together,
as compared with the results shown in Figure 3 and 4, these
results clearly indicate that a method in this study by detecting
the fluorescence of GFP-CL1 or immunoblot analysis using
FIGURE 4: Effects of expression of R-synuclein mutants on proteasome activity. (A, B) Immunoblot analyses of extracted proteins from cells
transfectedwithbothGFP-CL1andwild-typeR-synucleinoramutant(A30P,A53T,S129A,S129D,Δ73-83orβ-synuclein).Cellswereharvested
72 h after transfection, and Tris-soluble (lower panels) and SDS-soluble fractions (upper panels) were prepared. Immunoblot analyses were
performed using anti-GFP (upper panels) or anti-Syn102 (lower panels) antibodies. The results of quantitative analysis of the GFP-CL1 bands,
expressed as means þ SD (n = 3), are shown below the blot.
FIGURE 5: Measurements of proteasome activity using a fluorescent
peptide substrate. SH-SY5Y cells were transfected with pcDNA3
empty vector, wild-type R-synuclein (WT), A30P, A53T, S129D,
Δ73-83 for 72 h or treated with 20 μM MG132 for 6 h. Cytosolic
fractions were prepared and assayed using z-LLE-MCA as a sub-
strate. The results were expressed as means þ SD (n = 3).8020 Biochemistry, Vol. 48, No. 33, 2009 Nonaka and Hasegawa
anti-GFP antibody is a simple and sensitive for monitoring
proteasome activity in cells.
Small Molecular Compounds Attenuate Cellular Inhibi-
tion of Proteasome Activity by Expression of R-Synuclein.
In this study, we have shown that proteasomal activity is
impaired by expression of R-synuclein in SH-SY5Y cells. Im-
pairmentofproteasomefunctionleadstoinduction ofapoptosis,
followedbycelldeath,soitisimportanttoprotectcellsfromsuch
inhibition by intracellular R-synuclein. These results raised the
possibility that our cellular model, in which both GFP-CL1 and
R-synuclein are expressed, might be useful to screen for small
molecules preventing proteasome inhibition mediated by expres-
sion of R-synuclein. Recently, we have reported that several
compounds, including polyphenols, phenothiazines, and por-
phyrins, inhibit aggregation of recombinant R-synuclein in
vitro (35). We therefore asked whether these compounds might
affect proteasome inhibition by R-synuclein in cultured cells.
Compoundsofinterestwereadded totheculture mediumofcells
transfected with both GFP-CL1 and R-synuclein 2 h after
transfection. The cells were incubated for 72 h, harvested and
analyzed by immunoblotting and confocal laser microscopy.
Immunoblot analyses showed that the level of GFP-CL1 was
decreased significantly when cells were treated with purpurogal-
lin or myricetin (polyphenols), but not when they were treated
with ferric-dehydroporphyrin IX (porphyrin) (Figure 6A). Cells
treated with purpurogallin or myricetin displayed significant
decreases in GFP-CL1 fluorescence by confocal microscopy
(Figure 6B). Furthermore, we confirmed that exifone and
gossypetin, plant polyphenols inhibiting fibril formation of
R-synuclein in vitro (35), also attenuated R-synuclein-mediated
proteasome inhibition (data not shown). We further observed
that these small molecules did not affect R-synuclein expression
(Figure 6A). These results indicate that these compounds may
protect cells from proteasome dysfunction arising from expres-
sion of R-synuclein.
DISCUSSION
Recent studies have shown that aggregated and monomeric
R-synuclein inhibit proteasomal function in vitro (20, 21, 36). In
these reports, proteasome activity was measured in a cell-free
system using fluorescent peptide substrates, and little is known
about the effects of R-synuclein expression on proteasome
activity in cultured cells. To examine this question, we tried to
establish a sensitive and convenient method to measure protea-
some activity using cultured cells transfected with a GFP-CL1
reporter plasmid. We further applied this system to show that
transient coexpression of R-synuclein inhibits the proteasome
activity of SH-SY5Y cells.
The GFP-CL1 reporter is a useful tool for the detection of
proteasome activity in cells (26). Recently, Link et al. reported
thattheexpressionofGFP-CL1inCaenorhabditiselegansmuscle
or neurons causes deposition of GFP-CL1 and leads to rapid
paralysis (27). In this study, we also found that uncleaved GFP-
CL1 was largely recovered in TX-insoluble fractions of SH-
SY5Y cells transfected with GFP-CL1 and R-synuclein, while
R-synuclein was recovered in TS- and TX-soluble fractions
(Figure 1B andFigure S1 in Supporting Information), indicating
thatuncleavedGFP-CL1wasdeposited,butR-synucleinwasstill
soluble in transfected cells. Cell death was not detected in either
cells transfected with GFP-CL1 alone or cells transfected with
both GFP-CL1 and wild-type R-synuclein or mutants thereof,
althoughLinketal.foundthatGFP-CL1istoxicwhenexpressed
in C. elegans muscle cells (27). The discrepancy might be due to
differences in the cell type used. Further studies are required in
this regard. It is surprising that a relatively short addition of
16 residues to the C terminus of GFP can convert this normally
soluble protein into a protein that strongly aggregates. We
suggest that the C-terminal 16 residues may directly interfere
with GFP folding, resulting in misfolded (but still fluorescent)
forms that are prone to aggregate.
FIGURE 6: SmallmoleculespreventproteasomedysfunctionbyintracellularR-synuclein.SH-SY5YcellsweretransfectedwithGFP-CL1aloneor
both GFP-CL1 and R-synuclein. Compounds (final 40 μM) were added 2 h after transfection. Cells were harvested after a 72-h incubation and
analyzed by immunoblotting (A) and confocal microscopy (B). Immunoblot analyses of Tris-soluble (lower panels) and SDS-soluble fractions
(upper panels) were performed using anti-GFP (upper panels) or anti-Syn102 (lower panels) antibodies. The decreased GFP-CL1 level in
transfected cells treated with compound B or C, as compared with that of transfected cells treated with vehicle alone (DMSO), indicated that
compound B or C, but not compound A, rescued cells from proteasome impairment by expression of R-synuclein.Article Biochemistry, Vol. 48, No. 33, 2009 8021
How does R-synuclein suppress intracellular proteasome
activity? Several reports have described that R-synuclein may
directly interfere with the proteasome. It was shown that
R-synuclein binds to S60 or S6a, a component of the 19S subunit
in the 26S proteasome in cultured cells (23, 37). It was also
reported that aggregated R-synuclein, but not its monomer,
effectively inhibited the 26S proteasome activity in vitro (20, 21,
25, 36). Interestingly, we have shown that two pathogenic
R-synuclein mutants, A30P and A53T, which are liable to form
fibrils or oligomers in vitro, inhibited proteasome activity more
strongly than did wild-type R-synuclein, while Δ73-83 mutant
andβ-synuclein,neitherofwhichassembleintofilamentsinvitro,
did not inhibit proteasome activity. Although we failed to detect
any sarkosyl-insoluble aggregates of R-synuclein in cells trans-
fected with wild-type or mutant R-synuclein (data not shown),
these results raise the possibility that soluble prefibrillar inter-
mediates,suchasmisfoldedmonomers,oligomersorprotofibrils,
may inhibit proteasome activity in transfected cells. Additional
studies are needed to explore oligomers and protofibrils of
R-synuclein in our cell model.
Phosphorylation seems to be a common mechanism control-
ling the neurotoxicity of aggregation-prone toxic proteins in-
volved in neurodegenerative diseases such as tau (38, 39),
R-synuclein (3), and TDP-43 (40-42). We suggested that phos-
phorylation of R-synuclein may play a role in suppression of
proteasome activity in cells. It was reported that expression of
S129D mutant R-synuclein in Drosophila significantly enhances
the toxicity (34). However, the mechanisms through which
phosphomimetic S129D mutant causes cell death in the fly
remain unknown. Phosphorylated R-synuclein at Ser129 is
known to be more prone to aggregate than wild-type R-synu-
clein (3), and this may be related to its toxicity. Alternatively,
inhibitory effects of the S129D mutant on intracellular protea-
some activity, as shown in this study, may be involved in cell
death.
Importantly, we have shown that intracellular R-synuclein
may be toxic to neuronal cells because the protein causes
proteasome dysfunction. It was previously reported that du-
plication and triplication of R-synuclein gene causes familial
PD (7-11), indicating that overproduction of R-synuclein
protein could lead to the onset of PD. It is reasonable to
speculate that proteasome activity may also be affected in
neurons of these patients in a manner similar to that shown in
this study. It may be important to prevent R-synuclein-induced
inhibition or decrease of proteasome activity. In this study, we
screened for compounds protecting cells from the R-synuclein-
mediated proteasome dysfunction and found that purpuro-
gallin, myricetin, exifone, and gossypetin (polyphenols from
plants) prevented proteasome impairment by R-synuclein.
These compounds are thought to inhibit in vitro R-synuclein
filamentformation bystabilizingsolubleprefibrillarintermedi-
ates (35). We speculate that these small molecules may interact
witholigomericformsofR-synucleininculturedcells,although
we can not exclude the possibility that these compounds
directly regulate the activity of the proteasome. The precise
mechanisms by which these polyphenols prevent R-synuclein-
mediated proteasome dysfunction remain unknown. However,
these compounds may be novel drug candidates for neurode-
generative diseases. Our cellular model system using coexpres-
sion of GFP-CL1 and R-synuclein should be a sensitive and
useful tool for screening of compounds and drugs for the
prevention and treatment of these disease.
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